TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30145120
Drug: Lung cancer
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung cancer screening using low-dose CT with model incorporating nodule features and patient characteristics
Study: 26836927
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg three times a week for 8 weeks)
Study: 18330080
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/m2/day orally
Study: 18330080
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) plus 13-cis-retinoic acid (RA) 1 mg/kg/day orally
Study: 18330080
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) plus Interferon alpha-2a (IFN alpha-2a) 3 MU thrice a week intramuscular
Study: 8595082
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation T (10 mg nifedipine)
Study: 8595082
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation R (20 mg nifedipine)
Study: 327749
Drug: Stilbestrol treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stilbestrol treatment
Study: 29029278
Drug: Delafloxacin 300mg
Normalized name: DELAFLOXACIN 300MG/VIL INJ
DrugBank: Delafloxacin (DB11943)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Delafloxacin 300mg administered intravenously twice daily for 5-14 days
Study: 29029278
Drug: Vancomycin 15mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15mg/kg plus aztreonam 2g administered intravenously twice daily for 5-14 days
Study: 12798637
Drug: C4-V3 polypeptide
Normalized name: SH-polypeptide-42
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C4-V3 polypeptide vaccine emulsified in incomplete Freund's
Study: 12798637
Drug: Other vaccines
Normalized name: OTHER VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other vaccines and adjuvants studied
Study: 1680150
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral folic acid
Study: 6336928
Drug: 12% lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% lactate lotion
Study: 6336928
Drug: Nonlactated emollient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonlactated emollient lotion
Study: 26912003
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg/day for 7 days, then 400 mg/day for 7 days)
Study: 26912003
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent number of placebo tablets for 14 days)
Study: 25085076
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel, cisplatin, and 5‐fluorouracil (TPF)
Study: 25085076
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with surgery and postoperative radiation
Study: 768533
Drug: Aspirin-phenacetin-caffeine (APC)
Normalized name: aspirin / butalbital / caffeine / phenacetin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-phenacetin-caffeine (APC) plus codeine
Study: 19843482
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg IV q6h
Study: 19843482
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg IV q6h
Study: 18046889
Drug: Oral mucolytics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucolytics (daily therapy for at least 2 months)
Study: 18046889
Drug: Tiotropium and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium and inhaled corticosteroids (ICS)
Study: 18046889
Drug: Mucolytics
Normalized name: MUCOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucolytics
Study: 8990451
Drug: Methotrexate, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, 1 mg/kg intramuscularly, within 24 hours postoperatively
Study: 8250455
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (streptokinase, urokinase, rt-PA) followed by balloon angioplasty
Study: 3291526
Drug: 1 microgram
Normalized name: Alfacalcidol 1 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microgram dDAVP administered im every 12 h (N = 6)
Study: 3291526
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms dDAVP administered im every 12 h (N = 5)
Study: 3291526
Drug: 4 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 micrograms dDAVP administered im every 12 h (N = 4)
Study: 28266875
Drug: Levofloxacin-concomitant therapy
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-concomitant therapy for 10 days (n=55)
Study: 28266875
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (n=59)
Study: 20135899
Drug: Prophylactic antidepressants
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antidepressants
Study: 21355649
Drug: Video-feedback intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video-feedback intervention to promote positive parenting-child care (VIPP-CC)
Study: 16209160
Drug: Niacinamide-containing facial
Normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niacinamide-containing facial moisturizer applied to the face and one forearm twice daily for 4 weeks
Study: 9881074
Drug: Postoperative radiochemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiochemotherapy (RCT) + chemotherapy (CT)
Study: 7708069
Drug: Lipiodol chemoembolization
Normalized name: doxorubicin hydrochloride liposome Injection [LipoDox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiodol chemoembolization (70 mg of cisplatin, 10 ml of lipiodol, and gelatin‐sponge particles delivered through the hepatic artery)
Study: 7708069
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (treatment of complications and pain)
Study: 2706885
Drug: Heparin lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin lock catheter (n=17)
Study: 2706885
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous line (n=22)
Study: 139565
Drug: Spectinomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2 or 4 g once)
Study: 139565
Drug: Tetracycline (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (9 g orally for four days)
Study: 11436953
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment for 14 weeks
Study: 11436953
Drug: Sertraline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline group
Study: 29702133
Drug: Bio-K+ probiotic
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-K+ probiotic formulation (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, Lactobacillus rhamnosus CLR2)
Study: 24356624
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily) with paclitaxel (200 mg/m2 Q3W)/carboplatin (AUC 6 mg min/ml Q3W)
Study: 24356624
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks) with paclitaxel (200 mg/m2 Q3W)/carboplatin (AUC 6 mg min/ml Q3W)
Study: 22223702
Drug: Myo-inositol (MYO)
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol (MYO) 1200 mg/day for 12 weeks
Study: 21073267
Drug: Nurse-led patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led patient education programme and care plan (including lifestyle changes, home-based exercise training, weekly nurse consultations)
Study: 17714542
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of sucking and swallowing (one daily session of stimulation according to Vojta)
Study: 2782247
Drug: Controlled-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release isosorbide-5-mononitrate (ISMN) 60 mg daily
Study: 2782247
Drug: Immediate-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release isosorbide dinitrate (ISDN) 30 mg, 4 times daily
Study: 935199
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg, 6 doses, given at 6 hour intervals)
Study: 28213743
Drug: CER-001 (0.25-45.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001 (0.25-45.0 mg/kg)
Study: 28213743
Drug: CER-001 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-001 (2 mg/kg and above)
Study: 26531066
Drug: Accelerated, multiple,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated, multiple, double-dose HB vaccine (40 μg) administered at 0, 1, and 3 weeks before chemotherapy and additional three double doses post chemotherapy.
Study: 26531066
Drug: Conventional HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional HB vaccine (20 μg) administered at 0, 1, and 6 months.
Study: 23208320
Drug: Mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 100 mg single oral dose
Study: 16532442
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment (Thermage ThermaCool TC) delivered at 63.5 setting with medium-fast 1.5 cm2 tip over injected sites.
Study: 16532442
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with augmentation materials alone (no RF treatment).
Study: 12435653
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (N = 33)
Study: 12435653
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (N = 34)
Study: 2036245
Drug: levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole (2.5 mg/kg on two consecutive days every week except on chemotherapy days)
Study: 12816220
Drug: APC tonsillectomy
Normalized name: Recombinant human activated protein C (rH-APC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APC tonsillectomy (treatment B)
Study: 12816220
Drug: Conventional tonsillectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tonsillectomy (treatment A)
Study: 9145871
Drug: Artemisinin capsules
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin capsules (500 mg) administered with food
Study: 9145871
Drug: Artemisinin capsules
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin capsules (500 mg) administered without food
Study: 7698137
Drug: k-strophanthidin (0.0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: k-strophanthidin (0.0035 mg.kg-1 for 10 min)
Study: 2455126
Drug: Diltiazem (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (20 mg/l in Eurocollin's solution, bolus injection of 0.28 mg/kg, continuous infusion of 0.002 mg/min/kg for 2 days, then 60 mg orally twice daily)
Study: 2455126
Drug: Diltiazem treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem treatment group
Study: 29699757
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment period
Study: 27790252
Drug: 6% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% sodium hypochlorite (NaOCl) irrigation (single session treatment)
Study: 25436073
Drug: Alternate Sequential
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate Sequential Compression Device (ASCD)
Study: 25436073
Drug: Simultaneous Sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous Sequential Compression Device (SSCD)
Study: 23415342
Drug: Online Evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Evidence-based Medicine course (immediate intervention group, n=58)
Study: 20100336
Drug: Direct endomyocardial
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct endomyocardial autologous bone marrow cell injection
Study: 16368814
Drug: Nefopam 20
Normalized name: nefopam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 20 mg intraoperatively
Study: 16368814
Drug: Large-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large-dose remifentanil (Group L: 8 ng/mL)
Study: 16368814
Drug: Small-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose remifentanil (Group S: 3 ng/mL)
Study: 7715291
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and folinic acid (370-400 mg/m2 plus 200 mg/m2 daily for 5 days, every 28 days for 6 cycles)
Study: 2707458
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (100 mg) by mouth on cycle days 5 to 9
Study: 2707458
Drug: Treatment-independent pregnancies
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-independent pregnancies (before treatment or more than 1 month after therapy)
Study: 7343127
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (chemoprophylaxis) given every 15 days
Study: 28104830
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow oxygen therapy (HFOT)
Study: 14693596
Drug: Rocuronium 0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.60 mg/kg
Study: 7714113
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during euglycemic conditions
Study: 7714113
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during hyperglycemic conditions
Study: 7714113
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion during hyperglycemic vs euglycemic conditions
Study: 22818896
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of bevacizumab every 6 weeks for the first 3 injections followed by injections every 6 weeks (regimen A, n = 91)
Study: 22818896
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of bevacizumab every 12 weeks (regimen B, n = 94)
Study: 19206044
Drug: Orbital floor
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital floor triamcinolone acetonide injection
Study: 17189654
Drug: Home telemonitoring
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home telemonitoring of vital signs and respiration (weekly monitoring of 12 parameters, monthly 24-hour recording)
Study: 12040968
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ambroxol hydrochloride
Study: 12040968
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ambroxol hydrochloride
Study: 2533410
Drug: Sodium metabisulphite
Normalized name: Sodium metabisulphite
DrugBank: Sodium metabisulfite (DB15842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium metabisulphite aerosol (0.3 to 160 mg/ml)
Study: 2533410
Drug: Sodium metabisulphite
Normalized name: Sodium metabisulphite
DrugBank: Sodium metabisulfite (DB15842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium metabisulphite aerosol (PD20 dose)
Study: 2533410
Drug: Sodium metabisulphite
Normalized name: Sodium metabisulphite
DrugBank: Sodium metabisulfite (DB15842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium metabisulphite (second inhalation of same PD20 dose)
Study: 727428
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of domperidone
Study: 24750327
Drug: P/R +
Normalized name: Piperacillin/Tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: P/R + V (Peg‐IFNα2a and Ribavirin + E1E2MF59 vaccine)
Study: 22134600
Drug: CIDR protocol
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIDR protocol (controlled intravaginal progesterone releasing insert, 1.38 g of progesterone)
Study: 22134600
Drug: PGF2alpha analogue
Normalized name: PGF2alpha THAM
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2alpha analogue cloprostenol (0.5 mg per animal i.m.)
Study: 19554089
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E and allopurinol treatment for 3-5 days before surgery
Study: 17824352
Drug: Systematic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic treatment of depression in elderly individuals
Study: 9626221
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and 1-(2-chloroethyl)-3(2,6 dioxo-l-piperidyl)-1-nitrosource a (PCNU)
Study: 3610511
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride pump spray
Study: 31418814
Drug: aP-containing vaccines
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aP-containing vaccines
Study: 31418814
Drug: wP-containing vaccines
Normalized name: WP Thyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: wP-containing vaccines (control group)
Study: 31418814
Drug: wP-containing vaccines
Normalized name: WP Thyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: wP-containing vaccines
Study: 22916805
Drug: Pulse-based diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-based diet (two servings daily of beans, chickpeas, peas or lentils; about 150 g/d dry weight)
Study: 20165821
Drug: Metoclopramide injections
Normalized name: metoclopramide Injection
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide injections
Study: 20165821
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment (RT)
Study: 18701691
Drug: Paired associative
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired associative stimulation (PAS) at 8:00 P.M. after oral hydrocortisone (24 mg)
Study: 18701691
Drug: Oral hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrocortisone (24 mg)
Study: 10951799
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 ug) added to 20 ml of 0.125% bupivacaine
Study: 10951799
Drug: Ketamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (50 mg) added to 20 ml of 0.125% bupivacaine
Study: 7740948
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of cephalosporins 20 minutes before tourniquet inflation
Study: 28975432
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (1200 mg calcium, 96 mg magnesium, 2.4 mg zinc, 15 μg vitamin D, 4 g FOS-inulin per day)
Study: 28975432
Drug: Regular milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular milk (428 mg calcium per day)
Study: 26374911
Drug: hIVIG (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: hIVIG (0.25 g/kg)
Study: 25934631
Drug: Dietary nitrate
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary nitrate supplementation as beetroot juice (4.8 mmol twice a day for 3 days)
Study: 23632980
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy and appropriate medication
Study: 16787802
Drug: Multiple-dose activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose activated charcoal (G1)
Study: 16787802
Drug: Simple dose
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple dose of 1 g/kg activated charcoal (G2)
Study: 10741624
Drug: Probenecid (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (1,500 mg)
Study: 7756094
Drug: Feedback-controlled infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback-controlled infusions of omeprazole (target pH 5, dose range 0-12 mg h-1) with an initial bolus of 80 mg
Study: 7756094
Drug: Fixed-dose infusions
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose infusions of omeprazole (8 mg h-1) with an initial bolus of 80 mg
Study: 7756094
Drug: Initial bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus of 40 mg omeprazole followed by feedback-controlled infusions
Study: 7756094
Drug: Initial bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus of 80 mg omeprazole followed by feedback-controlled infusions
Study: 6155203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bleomycin and adriamycin (chemotherapy)
Study: 6155203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bleomycin and adriamycin with radiation (3600-4000 rad)
Study: 30877271
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion in MDD patients